Open AccessThe Exploration of the Clinical Treatment of Chronic Atrophic Gastritis
Author(s) -
Eerdunbageing
Publication year - 2019
Publication title -
journal of advances in medicine science
Language(s) - English
Resource type - Journals
eISSN - 2591-7617
pISSN - 2591-7609
DOI - 10.30564/jams.v2i4.1118
Subject(s) - medicine , atrophic gastritis , incidence (geometry) , gastroenterology , helicobacter pylori , adverse effect , statistical significance , gastritis , surgery , physics , optics
Purpose: To explore the effect of the clinical treatment of chronic atrophic gastritis Method: 70 patients with chronic atrophic gastritis treated in our hospital from October 2017 to November 2018 were selected and randomly divided into an observation group and a control group with 35 patients in each group. The control group received standard triad treatment with gastroprokinetic drug orally. On the basis of the control group, patients in the observation group received Xianlu Pazhu Wan. The treatment efficiency, eradication rate of helicobacter pylori (H. pylori), incidence of adverse effects and length of stay were compared between the two groups. Result: Compared with the control group, patients in the observation group had a higher treatment efficiency, higher H. pylori eradication rate, lower incidence of adverse effects, and shorter length of stay with statistical significance (P< 0.05). Conclusion: In the clinical treatment of patients with chronic atrophic gastritis, adding Xianlu Pazhu Wan into the basic medication plan can have a better treatment efficiency, reduce the incidence of adverse effects, and shorten the length of stay. Therefore, Xianlu Pazhu Wan should be promoted in the practice.